Spectrum Begins Phase III ZEST Study – Analyst Blog – NASDAQ
Spectrum Begins Phase III ZEST Study – Analyst BlogNASDAQThe study aims to evaluate the product in patients suffering from diffuse large B-cell lymphoma (DLBCL) and who are in remission after R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubici…
